Teladoc Health reported a Q2 revenue miss and significantly lowered its full-year sales guidance, leading to a substantial after-hours stock decline. While the company beat EPS estimates, the revenue and forward guidance disappointment are the primary drivers of negative market reaction.
Teladoc Health's Q2 earnings report revealed a revenue of $606.9 million, falling short of the Street's $615.4 million estimate. More critically, the company lowered its full-year sales guidance from a range of $2.481 billion to $2.576 billion to a new range of $2.362 billion to $2.447 billion, significantly below analyst expectations. This downward revision, particularly the projected decline in the BetterHelp segment, signals weakening demand and operational challenges, directly impacting investor confidence. The stock's 24.95% drop in after-hours trading reflects the immediate negative sentiment, indicating that the market is prioritizing revenue growth and future outlook over the slight EPS beat. This event poses a significant short-term risk for TDOC shareholders and could lead to further analyst downgrades.